The obesity pandemic

Therapy

Volumn 4, Issue 5, 2007, Pages 497-500

  Kurukulasuriya, L Romayne ^a   Sowers, James R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BEHAVIOR MODIFICATION; CALORIC RESTRICTION; CANCER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; EDITORIAL; EVIDENCE BASED MEDICINE; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL DISEASE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH BEHAVIOR; HEART DISEASE; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; OBESITY; OSTEOARTHRITIS; PANDEMIC; PHYSICAL ACTIVITY; PREVALENCE; PUBLIC HEALTH; RESPIRATORY TRACT DISEASE; SOCIAL PSYCHOLOGY; STEATORRHEA; SUICIDAL IDEATION; UNITED STATES; WEIGHT REDUCTION;

EID: 35348838498     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.5.497     Document Type: Editorial

References (15)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288(14), 1723-1727 (2002).
2. Daniels SR: The consequences of childhood overweight and obesity. Future child. 16(20), 47-67 (2006).
3. Malnick SDH, Knobler H: The medical complications of obesity. QJM 99(9), 565-579 (2006).
4. Sowers JR: Obesity as a cardiovascular risk factor. Am. J. Med. 115(Suppl. 8A), 37S-41S (2003).
5. Chakravarthy MV, Booth FW: Eating, exercise, and 'thrifty' genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. J. Appl. Physiol. 96, 3-10 (2004).
6. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E: Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 176(8), S1-S13 (2007).
7. Wing RR, Hill JO: Successful weight loss maintenance. Annu. Rev. Nutr. 21, 323-341 (2001).
8. Diabetes Prevention Program Research Group: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
9. Hofbauer KG, Nicholson JR, Boss O: The obesity epidemic: current and future pharmacological treatments. Annu. Rev. Pharmacol. Toxicol. 47, 565-592 (2007).
10. Li Z, Maglione M, Tu W et al.: Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 142, 532-546 (2005).
11. Davidson MH, Hauptman J, DiGirolamo M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281, 235-242 (1999).
12. Arterburn DE, Crane PK, Veenstra DL: The efficacy and safety of sibutramine for weight loss: a systematic review. Arch. Intern. Med. 164, 994-1003 (2004).
13. Despres JP, Golay A, Sjostrom L: Rimonabant in obesity-Lipid Study group effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353(20), 2121-2134 (2005).
14. Sjostrom L, Lindroos AK, Peltonen M et al.: Swedish obese subjects study scientific group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351(26), 2683-2693 (2004).
15. Adams TD, Gress RE, Smith SC et al.: Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357(8), 753-761 (2007).